LOGIN  |  REGISTER
Astria Therapeutics
Assertio

Azenta Announces Fiscal 2024 Third Quarter Earnings Conference Call and Webcast

July 24, 2024 | Last Trade: US$50.43 0.93 1.88

BURLINGTON, Mass., July 24, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2024 earnings which ended on June 30, 2024, on Tuesday, August 6, 2024, after the market closes.

The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 7, 2024.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

Sherry Dinsmore
This email address is being protected from spambots. You need JavaScript enabled to view it.

 
Chimerix

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB